Efavirenz and fat wasting—what might be happening?

Until very recently, fat wasting in HAART users was blamed on exposure to the drugs d4T and/or AZT, prolonged HIV infection or a combination of these. However, clinical trial results from the 14th CROI as well as test-tube studies conducted in France raise concerns about an additional drug—efavirenz—when it comes to the loss of subcutaneous fat.

According to laboratory experiments from France, efavirenz impacts the health of fat cells in a number of ways. This drug profoundly affects the ability of fat cells to produce some proteins that they need in order to grow and mature. Efavirenz does this by apparently suppressing the activity of key genes inside fat cells that produce these proteins.

In ACTG trial 5142 (reported earlier in this issue of TreatmentUpdate) there were three regimens tested as follows:

- lopinavir/r + efavirenz
- lopinavir/r + 2 nukes
- efavirenz + 2 nukes

Severe fat loss after two years was found in the following proportion of participants:

- efavirenz + 2 nukes – 32%
- lopinavir/r + 2 nukes – 17%
- lopinavir/r + efavirenz – 9%

A question that immediately arises is: Why did the combination of lopinavir/r + efavirenz result in the lowest level of lipoatrophy? Part of the answer may be that no nukes, particularly thymidine analogues such as d4T or AZT, were present. Also, test-tube research done in Canada and France suggests that ritonavir may be able to stimulate the growth of fat cells and, perhaps, counter the effect of efavirenz. This requires further laboratory study with experiments on fat cells, comparing the effect of lopinavir, ritonavir and efavirenz.

Nevirapine, the other licensed non-nuke, does not appear to cause any increased lipoatrophy, at least in one study.

Hopefully, investigations will begin looking into the effect of the experimental non-nukes TMC125 and TMC278 on fat wasting.

The fact that two clinical trials have found a significant loss of subcutaneous fat associated with the use of efavirenz is not a chance finding. The next step is unclear. Efavirenz is a potent and popular part of HAART, so the findings from ACTG 5142 may not be readily accepted by some physicians and their patients. Regulatory and research agencies could do the following:

- Convene an expert panel to assess the findings from ACTG 5142 and other studies on lipoatrophy and efavirenz.
- Initiate laboratory research to further study the underlying basis for the findings from ACTG 5142.
- Consider another clinical trial to confirm or refute ACTG 5142’s results.

REFERENCES:


2. Cameron DW, da Silva B, Arribas J, et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r
+ ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, February 25–28, 2007, Los Angeles, USA. Abstract 44LB.


Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at: